Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.

Mellema WW, Masen-Poos L, Smit EF, Hendriks LE, Aerts JG, Termeer A, Goosens MJ, Smit HJ, van den Heuvel MM, van der Wekken AJ, Herder GJ, Krouwels FH, Stigt JA, van den Borne BE, Haitjema TJ, Staal-Van den Brekel AJ, van Heemst RC, Pouw E, Dingemans AM.

Lung Cancer. 2015 Nov;90(2):249-54. doi: 10.1016/j.lungcan.2015.09.012. Epub 2015 Sep 15.

PMID:
26415993
2.

Difference in outcome between types of KRAS mutation may point toward difference in tumor biology.

Mellema WW, Dingemans AM, Jonker M, Smit EF.

J Thorac Oncol. 2015 Feb;10(2):e9. doi: 10.1097/JTO.0000000000000431. No abstract available.

3.

Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report.

Mellema WW, Burgers SA, Smit EF.

Lung Cancer. 2015 Feb;87(2):201-3. doi: 10.1016/j.lungcan.2014.11.014. Epub 2014 Nov 29.

PMID:
25488861
4.

Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.

Mellema WW, van der Hoek D, Postmus PE, Smit EF.

Lung Cancer. 2014 Oct;86(1):73-7. doi: 10.1016/j.lungcan.2014.07.017. Epub 2014 Aug 2.

PMID:
25129368
5.

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF, Bernards R.

Int J Cancer. 2015 Mar 15;136(6):1434-44. doi: 10.1002/ijc.29113. Epub 2014 Aug 8.

6.

EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?

Hendriks LE, Smit EF, Vosse BA, Mellema WW, Heideman DA, Bootsma GP, Westenend M, Pitz C, de Vries GJ, Houben R, Gr├╝nberg K, Bendek M, Speel EJ, Dingemans AM.

Lung Cancer. 2014 Apr;84(1):86-91. doi: 10.1016/j.lungcan.2014.01.006. Epub 2014 Jan 23.

PMID:
24529684
7.

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.

Mellema WW, Dingemans AM, Thunnissen E, Snijders PJ, Derks J, Heideman DA, Van Suylen R, Smit EF.

J Thorac Oncol. 2013 Sep;8(9):1190-5. doi: 10.1097/JTO.0b013e318298764e.

8.

A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.

Dingemans AM, Mellema WW, Groen HJ, van Wijk A, Burgers SA, Kunst PW, Thunnissen E, Heideman DA, Smit EF.

Clin Cancer Res. 2013 Feb 1;19(3):743-51. doi: 10.1158/1078-0432.CCR-12-1779. Epub 2012 Dec 6.

9.

Low molecular weight heparins in the treatment of lung cancer.

Mellema WW, Smit EF, Dingemans AM.

Expert Opin Investig Drugs. 2011 Nov;20(11):1517-22. doi: 10.1517/13543784.2011.625008. Epub 2011 Oct 7. Review.

PMID:
21978327

Supplemental Content

Loading ...
Support Center